Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics Inc. reports developments as a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company’s lead candidate, ONP-002, is an investigational intranasal neurosteroid being evaluated for concussion and mild traumatic brain injury, with updates centered on clinical trial operations, regulatory clearances, site activity and dosing milestones.
Company news also covers annual-report disclosures, operating and financial results, capital-structure actions, material agreements, shareholder voting matters and governance updates. Oragenics’ communications frequently connect its CNS strategy, intranasal delivery platform and public-company reporting obligations as an NYSE American-listed biotechnology issuer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Oragenics, Inc. (NYSE American: OGEN) has announced that CEO Kim Murphy will participate in the World Vaccine Congress in Washington, D.C., from April 3-6, 2023. The focus will be on the company's lead COVID-19 intranasal vaccine candidate, NT-CoV2-1, which has shown promising safety and immunogenicity results, paving the way for upcoming Phase 1 clinical trials. Oragenics recently entered a global license agreement with Inspirevax Inc. for a novel adjuvant, BDX301, to enhance NT-CoV2-1. This intranasal vaccine aims to provide advantages over injectable vaccines, including targeting mucosal immunity.
Oragenics, Inc. (NYSE American: OGEN) has reported positive results from third-party lab tests on its lantibiotics platform, targeting antibiotic-resistant infections. The tests showed that strains of Staphylococcus aureus (MRSA) and Enterococci (VRE) remain sensitive to Oragenics' compounds, despite resistance to standard therapies. This collaboration with Linnaeus Bioscience Inc. reinforces the efficacy of lantibiotics in combating serious infections. With over 2.8 million resistant infections annually in the U.S., Oragenics is focused on meeting this need through innovative antibiotic development.